Aoxing Pharmaceuticals (NYSE AMEX:AXN)

Aoxing Pharmaceutical Company, Inc., a specialty pharmaceutical company, through its subsidiary, Hebei Aoxing Pharmaceutical Co., Inc., engages in the research, development, manufacture, and distribution of various narcotics, neurological disorders, and pain-management products in the People’s Republic of China. Its product line includes prescription and over-the-counter pharmaceutical products. The company offers its products in various formulations, such as injection, tablets, capsules, oral solution, and powders. Its approved products include paracetamol and caffeine tablets, Zhongtong'an capsules, Naloxone Hydrochloride injection, Shuanghuanlian capsules, Ligustrazine Phosphate injection, and Xiaopiling granules; and narcotic pipeline products comprise Tilidine HCl tablets, oxycodone and paracetamol, Tilidine and Naloxone, compound codeine phosphate oral solution, Pholcodine oral syrup, and Buprenorphine and Naloxone sub lingual tablets. Aoxing Pharmaceutical Company sells its products primarily to hospitals, clinics, pharmacies, and retailers. The company has strategic alliance partnerships with QRx Pharma Ltd.; American Oriental Bio engineering, Inc.; and Phoenix Pharma labs, Inc. The company was formerly known as China Aoxing Pharmaceutical Co., Inc. and changed its name to Aoxing Pharmaceutical Company, Inc. in March 2010. The company was founded in 1655 and is based in Jersey City, New Jersey.

Reverse Merger Filing

Web site: http://www.aoxingpharma.com

Last updated February 10, 2011